Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06377566
Status:
RECRUITING
Last Update Posted:
2024-04-22
First Post:
2024-04-17
Brief Title:
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
BV-AVD in Patients With Newly-Diagnosed Early Stage Bulky Hodgkin Lymphoma Using a PET-adapted and MTV-guided Approach
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test whether BV-AVD is an effective treatment in people with early stage bulky Hodgkin lymphoma that was recently diagnosed and who have not yet received any treatments for their disease
BV is a type of drug called an antibody-drug conjugate ADC ADCs are a substance made up of a monoclonal antibody chemically linked to a drug Antibodies are proteins made by the immune system to fight infections and other possible harms to the body The monoclonal antibody binds to specific proteins or receptors found on certain types of cells including cancer cells The linked drug enters these cells and kills them without harming other cells Researchers think BV may be an effective treatment for this type of cancer because the drug targets cells that have CD30 which play a role in cancer cell growth By destroying these cells BV may help slow or stop the growth of the cancer AVD doxorubicin vinblastine and dacarbazine is a treatment regimen that works by stopping the growth of cancer cells either by killing the cells or by stopping them from dividing The researchers think that BV in combination with AVD may work better than AVD alone to slow or stop the growth of the cancer
BV is a type of drug called an antibody-drug conjugate ADC ADCs are a substance made up of a monoclonal antibody chemically linked to a drug Antibodies are proteins made by the immune system to fight infections and other possible harms to the body The monoclonal antibody binds to specific proteins or receptors found on certain types of cells including cancer cells The linked drug enters these cells and kills them without harming other cells Researchers think BV may be an effective treatment for this type of cancer because the drug targets cells that have CD30 which play a role in cancer cell growth By destroying these cells BV may help slow or stop the growth of the cancer AVD doxorubicin vinblastine and dacarbazine is a treatment regimen that works by stopping the growth of cancer cells either by killing the cells or by stopping them from dividing The researchers think that BV in combination with AVD may work better than AVD alone to slow or stop the growth of the cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None